MiraLAX Use in Patients with Colostomy
Yes, a patient with a colostomy can safely take MiraLAX (polyethylene glycol 3350) for colonic stool burden seen on CT, as PEG is an effective osmotic laxative that works systemically throughout the colon, including the segment proximal to the stoma.
Mechanism and Rationale
PEG 3350 is an osmotic laxative that draws water into the colonic lumen, softening stool and promoting bowel movements 1. The medication works on the entire colon, not just the distal segments, making it appropriate for patients with colostomies where stool burden may accumulate in the proximal colon before reaching the stoma.
Dosing Recommendations
- Standard dose: 17 g once daily mixed in 8 ounces of liquid 1, 2
- Can be titrated based on response
- Duration: Proven safe and effective for up to 6-12 months of continuous use 1, 3
Safety Profile in Colostomy Patients
The key consideration is monitoring for high ostomy output (HOO), which is defined as output >1.5 L/day 4. While HOO is more common with ileostomies than colostomies, PEG's osmotic effect could theoretically increase stomal output.
Monitoring Strategy:
- Start at standard dose (17 g daily)
- Monitor stomal output volume for first few days
- Watch for signs of dehydration (decreased urine output, dizziness, weakness)
- If output becomes excessive, reduce dose or discontinue
Expected Side Effects
Common side effects include 1:
- Diarrhea or loose stools (158 more per 1,000 treated)
- Abdominal distension
- Flatulence
- Nausea
These effects are generally mild to moderate and consistent with the medication's laxative action.
Important Caveats
Electrolyte monitoring: While PEG 3350 without electrolytes has shown no clinically significant electrolyte disturbances in standard populations 3, patients with colostomies may have baseline electrolyte abnormalities. Consider checking a basic metabolic panel if using for extended periods or if the patient develops symptoms.
Avoid in complete obstruction: Ensure the stool burden represents constipation rather than mechanical obstruction distal to the stoma, which would be a contraindication.
Hydration: Ensure adequate fluid intake (8 ounces with each dose minimum) 1
Clinical Effectiveness
- Increase of 2.9 complete spontaneous bowel movements per week vs placebo
- 42% responder rate using FDA endpoints
- Durable response over 6-24 weeks
The medication should produce results within 1-3 days of initiation, with stool softening and increased frequency of output through the stoma.
Alternative Consideration
If PEG causes excessive stomal output or is poorly tolerated, magnesium oxide could be considered as an alternative osmotic agent, though it requires dose adjustment in renal insufficiency 1.